[go: up one dir, main page]

WO2009147400A1 - Milieux de culture de cellules souches et procédés correspondants - Google Patents

Milieux de culture de cellules souches et procédés correspondants Download PDF

Info

Publication number
WO2009147400A1
WO2009147400A1 PCT/GB2009/001404 GB2009001404W WO2009147400A1 WO 2009147400 A1 WO2009147400 A1 WO 2009147400A1 GB 2009001404 W GB2009001404 W GB 2009001404W WO 2009147400 A1 WO2009147400 A1 WO 2009147400A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture medium
agonist
acid
cells
supplement
Prior art date
Application number
PCT/GB2009/001404
Other languages
English (en)
Inventor
Robert Scott Mcrae
Original Assignee
Iti Scotland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0810304A external-priority patent/GB0810304D0/en
Priority claimed from GB0821363A external-priority patent/GB0821363D0/en
Application filed by Iti Scotland Limited filed Critical Iti Scotland Limited
Publication of WO2009147400A1 publication Critical patent/WO2009147400A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones

Definitions

  • the invention is in the field of stem cell culture media and methods, in particular culture media and methods for expanding populations of pluripotent stem cells, e.g. human embryonic stem (liES) cells.
  • pluripotent stem cells e.g. human embryonic stem (liES) cells.
  • pluripotent stem cells there is great interest in culture media and methods for expanding populations of pluripotent stem cells, particularly hES cells which are especially difficult to culture.
  • Clinical and research applications of pluripotent stem cells require reproducible cell culture methods to provide adequate numbers of cells of suitable quality. Numerous different culture media and methods have been tested for pluripotent stem cells, with varying degrees of success.
  • hES cells were originally derived using mouse embryonic fibroblasts (mEFs) as feeder cells (Thomson et al. (1998) Science 282:1145-1147). hES cells are still commonly maintained using human or murine embryonic fibroblasts as feeder cells, or as a source of conditioned medium (or both).
  • mEFs mouse embryonic fibroblasts
  • the use of feeder cells is undesirable, because it complicates passaging of the stem cells (the stem cells must be separated from the feeder cells at each passage, and new feeder cells are required at each passage).
  • the use of feeder cells can also lead to contamination of the stem cells with the feeder cells, complicating analysis of the results of any experiments performed on the stem cells.
  • pluripotent stem cell culture media and methods in particular for improvements to hES cell culture media and methods.
  • the invention provides new culture media and methods for pluripotent stem cells, which provide significant advantages over known culture media and methods.
  • the invention also provides related culture medium supplements, compositions and uses.
  • An advantage of the culture media of the invention is that they can be used to culture pluripotent stem cells without feeder cell contact, i.e. they can be used to culture pluripotent stem cells in the absence of a layer of feeder cells.
  • Another advantage of the culture media of the invention is that they can be used to rapidly expand a population of pluripotent stem cells, i.e. they allow large numbers of cells to be produced in a relatively short time.
  • a further advantage of the culture media of the invention is that they can be used to expand several different types of pluripotent stem cell lines, i.e. different types of pluripotent stem cell can be cultured using a single culture medium.
  • culture media of the invention can be used without a step of adapting cells to the culture medium, as is commonly required when transferring pluripotent stem cells into a new culture medium.
  • the culture media of the invention therefore provide significant advantages over known culture media in terms of the scalability, reproducibility and robustness of pluripotent stem cell culture.
  • the culture media of the invention comprise, amongst other ingredients, a farnesoid X receptor (FXR) agonist, a retinoid X receptor (RXR) or retinoic acid receptor (RAR) agonist, a peroxisome proliferator-activated receptor (PPAR) agonist, and/or a thyroid hormone receptor (THR) agonist.
  • FXR farnesoid X receptor
  • RXR retinoid X receptor
  • RAR retinoic acid receptor
  • PPAR peroxisome proliferator-activated receptor
  • THR thyroid hormone receptor
  • the FXR, RXR, RAR, PPAR and THR are all members of the nuclear hormone receptor superfamily, which means they are all ligand- activated transcription factors, and they are functionally inter-linked by virtue of their hetero-dimerisation upon activation by ligands ⁇ e.g.
  • the invention provides a culture medium for expanding a population of pluripotent stem cells, which comprises a farnesoid X receptor (FXR) agonist, a retinoid X receptor (RXR) or retinoic acid receptor (RAR) agonist, a peroxisome proliferator- activated receptor (PPAR) agonist, and/or a thyroid hormone receptor (THR) agonist.
  • the culture medium may comprise an FXR agonist, an RXR or RAR agonist and a THR agonist.
  • the culture medium may comprise an FXR agonist, an RXR or RAR agonist, a PPAR agonist and a THR agonist.
  • the invention also provides a culture medium supplement that comprises an FXR agonist, an RXR or RAR agonist, a PPAR agonist and/or a THR agonist.
  • the invention also provides a hermetically-sealed vessel containing a culture medium or culture medium supplement of the invention.
  • the invention also provides a method for preparing a culture medium as disclosed herein, comprising the steps of: (a) obtaining a culture medium; and (b) adding an FXR agonist, an RXR or RAR agonist, a PPAR agonist and/or a THR agonist to the culture medium.
  • the invention also provides a composition comprising: (a) a culture medium according to the invention; and (b) stem cells.
  • the invention also provides a composition containing: (a) a culture medium according to the invention; and (b) an extracellular matrix material.
  • the invention also provides the use of a culture medium of the invention for expanding a population of pluripotent stem cells.
  • the invention also provides a method for expanding a population of pluripotent stem cells, comprising: (a) providing a population of pluripotent stem cells; (b) providing a culture medium of the invention; (c) contacting the stem cells with the culture medium; and (d) culturing the cells under appropriate conditions.
  • the invention also provides the use of an FXR agonist, an RXR or RAR agonist, a PPAR agonist and/or a THR agonist for pluripotent stem cell culture.
  • the specific ingredients of the culture media, supplements and compositions of the invention can vary according to particular needs and applications. Likewise, the precise steps of the methods of the invention can vary according to particular needs and applications.
  • the culture media, supplements, methods, compositions and uses according to this invention may be optimised by routine experimentation. For example, if a culture medium, supplement or composition fails to give the desired level of pluripotent stem cell expansion, variables such as the amount of each ingredient in the culture medium or supplement, seeding densities, culture conditions, culture periods, etc. can be altered in further experiments.
  • the amount of each of the ingredients described herein can be optimised independently of the other ingredients by routine optimisation or one or more ingredients can be added or removed.
  • a culture medium can be tested for its ability to support expansion of pluripotent stem cells by testing it alongside or in place of a known culture medium or method.
  • Pluripotent stem cells and cell culture reagents and apparatus for use in the invention are available commercially, e.g. from Cellartis AB (G ⁇ teborg, Sweden), VitroLife AB (Kungsbacka, Sweden), GIBCO ® (Invitrogen), Millipore Corporation (Billerica, Massachusetts), Sigma ® (St. Louis, Missouri) and Biomol International L.P. (Exeter, UK).
  • the culture media of the invention may comprise an FXR agonist, and the invention provides the use of an FXR agonist for pluripotent stem cell culture.
  • the FXR (also known as NRH 14) is a member of the nuclear hormone receptor superfamily (i.e. it is a ligand-activated transcription factor) and is involved in the control of multiple cellular pathways.
  • the FXR is expressed from a single gene in humans (NRHl 4), although four isoforms are generated by alternative splicing.
  • An 'FXR agonist' is an agent that binds to and activates at least one FXR isoform.
  • Various methods for determining if a given substance is an FXR agonist are known and might be used in conjunction with this invention. For example, determining whether a given substance is an FXR agonist may involve analysing whether the substance induces or represses the expression of FXR target genes, e.g.
  • SHP short heterodimer partner
  • PLTP phospholipid transport protein
  • BSEP canalicular bile salt export pump
  • IBABP ileum bile acid binding protein
  • determining whether a given substance is an FXR agonist may involve testing the substance using a cell-based luciferase assay or using a surface plasmon resonance (SPR) coactivator association assay (e.g. as described in Fujino et al. (2004) Journal of Lipid Research 45:132-138).
  • SPR surface plasmon resonance
  • Bile acids, bile acid intermediates and polyunsaturated fatty acids are all known to be FXR agonists in vitro, and several synthetic FXR agonists have been generated (see Claudel et al. (2005) Arterioscler. Thromb. Vase. Biol. 25:2020-2030; Chiang (2002) Endocrine Reviews 23(4):443-463; Houten et al. (2006) EMBO Journal 25:1419- 1425; and Soisson et al. (2008) PNAS vol. 105 no. 14:5337-5342).
  • An FXR agonist in a culture medium of the invention may be a cholesterol metabolite, such as a bile acid or a bile acid intermediate.
  • Bile acids are steroid carboxylic acids derived from cholesterol. All bile acids comprise two connecting units, a rigid steroid nucleus and a short aliphatic side chain. The steroid nucleus of bile acids has the saturated tetra-cyclic hydrocarbon perhydrocyclo-pentanophenanthrene, containing three six-member rings and a five-member ring. In addition, there are angular methyl groups at positions C- 18 and C-19.
  • Bile acids are facially amphipathic molecules which contain a side chain that terminates in a carboxyl group (see Mukhopdhyay & Maitra (2004) Current Science 87(12):1666-1683).
  • the principle bile acids in humans are the primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA), and the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA).
  • the FXR agonist is cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA) or lithocholic acid (LCA).
  • Bile acids are often conjugated to glycine or taurine (e.g. to form glycocholic acid or taurocholic acid for CA), and these conjugates may also be used in the culture media of the invention.
  • glycocholic acid, taurocholic acid, glycodeoxycholic acid or taurodeoxycholic acid may be used.
  • a bile acid or a bile acid intermediate may be used, it may be provided in the form of a bile salt, preferably in the form of a sodium salt.
  • An FXR agonist in a culture medium of the invention may be a polyunsaturated fatty acid (PUFA), such as an arachidonic acid, linolenic acid or docosahexaenoic acid.
  • PUFA polyunsaturated fatty acid
  • an FXR agonist may be ⁇ -linolenic acid (ALA), ⁇ -linolenic acid (GLA) or di-homo- ⁇ -linolenic acid (DGLA, also sometimes referred to as DiHLA).
  • ALA ⁇ -linolenic acid
  • GLA ⁇ -linolenic acid
  • DGLA di-homo- ⁇ -linolenic acid
  • the inventor's data show that DGLA provides improved stem cell expansion relative to other linolenic acids.
  • the invention therefore also provides the use of DGLA for pluripotent stem cell culture, and a culture medium for expanding pluripotent stem cells that comprises DGLA.
  • An FXR agonist in a culture medium of the invention may be a synthetic FXR agonist, such as MFA-I (e.g. see Soisson et al. (2008) PNAS), GW4064 ⁇ e.g. see Maloney et al (2000) J. Med. Chem. 43:2971-2974) or 6 ⁇ -ethyl-CDCA (6-ECDCA) (e.g. see Houten et al. (2006) EMBO Journal 25:1419-1425).
  • MFA-I e.g. see Soisson et al. (2008) PNAS
  • GW4064 ⁇ e.g. see Maloney et al (2000) J. Med. Chem. 43:2971-297
  • 6-ECDCA 6 ⁇ -ethyl-CDCA
  • Farnesol, forskolin, androsterone or etiocholanolone might also be useful as FXR agonists in the culture media of the invention (e.g. see Howard et al. (2000) Toxicol Appl Pharmacol. 163(2):195-202).
  • Retinoid X receptor RXR
  • RAR retinoic acid receptor
  • the culture media of the invention may comprise an RXR or RAR agonist, and the invention provides the use of an RXR or RAR agonist for pluripotent stem cell culture.
  • the retinoid receptors are members of the nuclear hormone receptor superfamily (i. e. they are ligand-activated transcription factors) and are involved in the control of multiple cellular pathways.
  • the two families of retinoid receptors each consist of three receptor types ( ⁇ , ⁇ , ⁇ ) encoded by different genes, and multiple isoforms are generated by alternative splicing.
  • RXRs and RARs are functionally inter-linked, because RARs function as heterodimers with RXRs.
  • RXRs can also form homodimers, as well as heterodimers with other nuclear hormone receptors such as PPAR (see Aranda & Pascual (2001) Physiol Rev 81:1269-1304; Szanto et al. (2004) Cell Death and Differentiation 11 :S126-S143; Germain et al. (2006) Pharmacological Reviews 58:712- 725; and Germain et al. (2006) Pharmacological Reviews 58:760-772).
  • PPAR nuclear hormone receptor
  • An 'RXR or RAR agonist' is an agent that binds to and activates at least one RXR or RAR receptor type ( ⁇ , ⁇ , ⁇ ) or isoform (splice variant).
  • RXR or RAR receptor type ⁇ , ⁇ , ⁇
  • isoform splice variant
  • determining whether a given substance is an RXR or RAR agonist may involve analysing whether the substance induces or represses the expression of RXR target genes.
  • determining whether a given substance is an RXR or RAR agonist may involve testing the substance using a reporter gene assay system (e.g. see the methods of Perlmann et al.
  • RXR agonists include 9-cis-retinoic acid (9cRA), methoprene acid (MPA) 5 methoprenic acid, docosahexaenoic acid, phytanic acid, UAB20, UAB30, 4-methyl-UAB30, UAB76, UABl 12, CD3254, LG100268, LGD1069 (targretin), AGN194204 and SRl 1237 (see e.g. Germain et al (2006) Pharmacological Reviews 58:760-772).
  • 9cRA 9-cis-retinoic acid
  • MPA methoprene acid
  • docosahexaenoic acid docosahexaenoic acid
  • phytanic acid UAB20, UAB30, 4-methyl-UAB30, UAB76, UABl 12, CD3254, LG100268, LGD1069 (targretin), AGN194204 and SRl 1237 (see e.g. Germain et al (2006) Pharma
  • RAR agonists include 9-cis- retinoic acid (9cRA), AGN195183, Am580, TTNPB, Am80, CO666, BMS270394, BMS961, BMS641 and BMS753 (see e.g. Germain et al. (2006) Pharmacological Reviews 58:712-725). It is envisaged that any of these natural and synthetic RAR and RXR agonists may be useful in the culture media of the invention.
  • An RXR or RAR agonist in a culture medium of the invention may be a retinoid.
  • the term 'retinoid' is commonly used to refer to dietary Vitamin A (retinol), retinol metabolites, and synthetic analogues thereof.
  • Retinoids are typically compounds that comprise four isoprenoid units joined in a head-to-tail manner.
  • An RXR or RAR agonist used in the invention may be a first generation retinoid (e.g. retinol, retinal, tretinoin, isotretinoin or alitretinoin), a second generation retinoid (e.g. etretinate or its metabolite acitretin) or a third generation retinoid (e.g. tazarotene, bexarotene or adapalene).
  • first generation retinoid e.g. retinol, retinal, tretinoin, isotreti
  • An RXR or RAR agonist in a culture medium of the invention may be a rexinoid.
  • the term 'rexinoid' is commonly used to refer to synthetic RXR-specific agonists.
  • Known rexinoids include SRl 1237, LG 100268 and LGD 1069 (see Germain et al. (2006) Pharmacological Reviews 58:760-772).
  • the RXR or RAR agonist is a retinol, retinal or retinoic acid.
  • the RXR or RAR agonist may be all-trans-retinol (ATR) 5 13-cis-retinol (13cROL), 11-cis-retmal, retinyl acetate (RETACT) 5 4-hydroxy-retinoic acid (4HRA), 13-cis-retinoic acid (13cRA) or 9-cis-retinoic acid (9cRA).
  • TPAR Peroxisome proliferator-activated receptor
  • the culture media of the invention may comprise a PPAR agonist, and the invention provides the use of a PPAR agonist for pluripotent stem cell culture.
  • the peroxisome proliferator-activated receptors are members of the nuclear hormone receptor superfamily (i.e. they are ligand-activated transcription factors) and are involved in the control of multiple cellular pathways.
  • the PPARs exhibit broad, isotype-specific, tissue expression patterns. All of the PPARs function via heterodimerisation with the retinoid X receptor (RXR).
  • a 'PPAR agonist' is an agent that binds to and activates at least one PPAR type (i.e. at least one of PPAR ⁇ , PPAR ⁇ and PPAR ⁇ ).
  • Various methods for determining if a given substance is a PPAR agonist are known and might be used in conjunction with this invention. For example, determining if a given substance is a PPAR agonist may involve analysing whether the substance induces or represses the expression of PPAR target genes, e.g.
  • ACS acyl-coenzyme A synthetase
  • MCPT-I muscle-type carnitine palmitoyltransferase- 1
  • LCAD long-chain acyl-coenzyme A dehydrogenase
  • determining if a given substance is a PPAR agonist may involve analysing whether the substance induces or represses the expression of a reporter gene under the control of a PPAR response element, or may involve using a Scintillation Proximity Assay (SCA), a Differential Protease Sensitivity Assay (DPSA), a Ligand Induced Complex (LIC) assay and/or a Coactivator-Dependent Receptor Ligand Assay (CARLA) (e.g. see the methods described in Desvergne & Wahli (1999) Endocrine Reviews 20(5):649-688).
  • SCA Scintillation Proximity Assay
  • DPSA Differential Protease Sensitivity Assay
  • LIC Ligand Induced Complex
  • CARLA Coactivator-Dependent Receptor Ligand Assay
  • Natural PPAR agonists include unsaturated fatty acids such as ⁇ 3-PUFAs (e.g. ⁇ - linolenic acid, ⁇ -linolenic acid, eicosapentaenoic acid and docohexaenoic acid), ⁇ 6- PUFAs (e.g. linolenic acid, dihomo- ⁇ -linoleic acid and arachidonic acid), ⁇ 9-mUFAs (e.g. palmitoleic acid, oleic acid, elaidic acid, erucic acid and nervonic acid) and ⁇ 2- mUFAs (petroselinic acid).
  • ⁇ 3-PUFAs e.g. ⁇ - linolenic acid, ⁇ -linolenic acid, eicosapentaenoic acid and docohexaenoic acid
  • ⁇ 6- PUFAs e.g. linolenic acid, di
  • Natural PPAR ligands also include saturated fatty acids (such as capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid and behenic acid), dicarboxylic fatty acids (such as dodecanedoic acid) and eicosanoids (such as 8-HEPE, 8-HETE, 8S-HETE, 8R-HETE, 12-HETE, Leukotriene B4, 9-HODE and 13-HODE).
  • saturated fatty acids such as capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid and behenic acid
  • dicarboxylic fatty acids such as dodecanedoic acid
  • eicosanoids such as 8-HEPE, 8-HETE, 8S-HETE, 8R-HETE, 12-HETE, Leukotriene B4, 9-HODE and 13-HODE.
  • Synthetic PPAR ligands include prostaglandin 12 analogs (such as carbaprostacyclin, iloprost and cicaprost), leukotriene B4 analogs (such as trifluoromethyl leukotriene B4, ZK 151657 and ZK 158252), leukotriene D4 antagonists (such as Ly 171883), hypolipidemic agents (such as clofibric acid, ciprofibric acid, bezafibric acid, fenofibric acid, pirixinic acid (Wy-14643), GW 2331, GW 2433 and eicosatetraynoic acid), hypoglycemic agents (thiazolidinediones, such as rosiglitazone (BRL 49653), AD-5075, troglitazone (CD-045), pioglitazone, and ciglitazone), hypolipidemic and hypoglycaemic agents (non-thiazolidinedione
  • the PPAR agonist may be a glitazone.
  • Glitazones are synthetic PPAR agonists that activate PPAR ⁇ , and include rosiglitazone, troglitazone, pioglitazone, and ciglitazone.
  • the PPAR agonist may be a glitazar.
  • Glitazars are synthetic PPAR agonists that activate both PPAR ⁇ and PPAR ⁇ , and include muraglitazar, tesaglitazar, ragaglitazar, reglitazar and farglitazar.
  • the PPAR agonist may be a fibric acid derivative (fibrate), such as clofibrate (or clofibric acid), bezafibrate (or bezafibric acid), ciprofibrate (or ciprofibric acid), fenofibrate (or fenofibric acid), etofibrate, or gemfibrozil.
  • fibric acid derivative such as clofibrate (or clofibric acid), bezafibrate (or bezafibric acid), ciprofibrate (or ciprofibric acid), fenofibrate (or fenofibric acid), etofibrate, or gemfibrozil.
  • Known PPAR agonists also include plialate monoesters ⁇ e.g.
  • Thyroid hormone receptor (THR) agonists Thyroid hormone receptor (THR) agonists
  • the culture media of the invention may comprise a THR agonist.
  • the invention also provides the use of a THR agonist for pluripotent stem cell culture.
  • the THR is a member of the nuclear hormone receptor superfamily ⁇ i.e. it is a ligand- activated transcription factor) that is activated in vivo via binding to the tyrosine-based thyroid hormones tri-iodothyronine (T3) and thyroxine (T4) produced by the thyroid gland.
  • T3 tri-iodothyronine
  • T4 thyroxine
  • Activation of the THR has multiple effects in vivo (see Yen (2001) Physiol. Rev. 81:1097-1142; Goglia (2005) Biochemistry (Moscow) 70(2):203-213; Pinna et al. (2002) Endocrinology 143(5):1789-1800; Lombardi et al. (2000) 141(5):1729 ⁇ 1734).
  • THR- ⁇ l THR- ⁇ 2
  • THR- ⁇ l THR- ⁇ 2
  • An 'THR agonist' is an agent that binds to and activates at least one THR type ⁇ i.e. at least one of THR- ⁇ l, THR- ⁇ 2, THR- ⁇ l and THR- ⁇ 2).
  • THR- ⁇ l a THR agonist
  • determining if a given substance is a THR agonist may involve analysing whether the substance induces or represses the expression of endogenous THR target genes.
  • determining if a given substance is a THR agonist may involve analysing whether the substance induces or represses the expression of a reporter gene under the control of a thyroid hormone response element (TRE) (e.g. see the methods cross-referenced in Yen (2001) Physiol. Rev. 81:1097-1142).
  • TRE thyroid hormone response element
  • a THR agonist in a culture medium of the invention may be an iodothyronine (i. e. an iodinated derivative of thyronine).
  • a THR agonist may be a di-iodothyronine, a tri- iodothyronine or a tetra-iodothyronine.
  • a THR agonist may be 3,5-di- iodothyronine (3,5-T 2 ), 3,5-diiodo-L-tyrosine dihydrate (DLTdH), 3,3'-di-iodothyronine
  • the THR agonist is 3,5-diiodo-L-thyronine (3,5-DLT).
  • the THR agonist may be a synthetic THR agonist, e.g. the heterocyclic thyromimetic GC-I (e.g. see Manzano et al. (2003) Endocrinology 144(12):5480-5487 and Flamant et al. (2006) Pharmacological Reviews 58:705-711).
  • a synthetic THR agonist e.g. the heterocyclic thyromimetic GC-I (e.g. see Manzano et al. (2003) Endocrinology 144(12):5480-5487 and Flamant et al. (2006) Pharmacological Reviews 58:705-711).
  • the culture media of the invention contain a nuclear hormone receptor (NHR) agonist.
  • the culture media of the invention may comprise two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, or twelve or more, different NHR agonists.
  • the culture media of the invention comprise an FXR agonist, an RXR or RAR agonist, a PPAR agonist and/or a THR agonist.
  • the culture media may comprise two or more, three or more, four or more, or five or more, different FXR agonists.
  • the culture media of the invention may comprise two or more, three or more, four or more, or five or more, different RXR or RAR agonists.
  • the culture media of the invention may comprise two or more, three or more, four or more, or five or more, different PPAR agonists.
  • the culture media of the invention may comprise two or more, three or more, four or more, or five or more, different THR agonists.
  • a culture medium of the invention comprises an FXR agonist, an RXR or RAR agonist and a THR agonist. In other embodiments, a culture medium of the invention comprises an FXR agonist, an RXR or RAR agonist, a PPAR agonist and a THR agonist.
  • a culture medium of the invention may comprise between about lOpM and about 10OmM of an FXR agonist, between about lOpM and about 10OmM of an RXR or RAR agonist, between about lOpM and about 10OmM of a PPAR agonist, and/or between about lOpM and about 10OmM of a THR agonist.
  • a culture medium of the invention may comprise at least about lOpM of an FXR agonist, at least about lOpM of an RXR or RAR agonist, at least about lOpM of a PPAR agonist, and/or at least about lOpM of a THR agonist.
  • a culture medium of the invention may comprise between about 10OnM and about ImM of an FXR agonist.
  • a culture medium may comprise between about 250 and about 75OnM of an FXR agonist, between about 300 and about 70OnM of an FXR agonist, between about 350 and about 65OnM of an FXR agonist, between about 400 and about 60OnM of an FXR agonist, between about 450 and about 55OnM of an FXR agonist, or about 50OnM of an FXR agonist.
  • a culture medium may comprise between about 250 and about 75OnM of cholic acid, between about 300 and about 70OnM of cholic acid, between about 350 and about 65OnM of cholic acid, between about 400 and about 60OnM of cholic acid, between about 450 and about 55OnM of cholic acid, or about 50OnM of cholic acid.
  • a culture medium of the invention may comprise between about InM and about ImM of an RXR or RAR agonist.
  • a culture medium may comprise between about 10 and about 50OnM of an RXR or RAR agonist, between about 20 and about 40OnM of an RXR or RAR agonist, between about 25 and about 35OnM of an RXR or RAR agonist, or between about 30 and about 30OnM of an RXR or RAR agonist.
  • a culture medium may comprise between about 10 and about 50OnM of all trans retinol, between about 20 and about 40OnM of all trans retinol, between about 25 and about 35OnM of all trans retinol, or between about 30 and about 30OnM of all trans retinol.
  • a culture medium of the invention may comprise between about
  • a culture medium may comprise between about 1 OnM and about 750 ⁇ M of a PPAR agonist, between about 25nM and about 500 ⁇ M of a PPAR agonist, between about 5OnM and about 250 ⁇ M of a PPAR agonist, or between about 75nM and about lOO ⁇ M of a PPAR agonist.
  • a culture medium may comprise about lO ⁇ M of a PPAR agonist.
  • a culture medium of the invention may comprise between about InM and about 10OmM of a THR agonist.
  • a culture medium may comprise between about 25 and about 75nM of a THR agonist, between about 30 and about 7OnM of a THR agonist, between about 35 and about 65nM of a THR agonist, between about 40 and about 6OnM of a THR agonist, between about 45 and about 55nM of a THR agonist, or about 5OnM of a THR agonist.
  • a culture medium may comprise between about 25 and about 75nM of 3,5-diiodo-L-thyronine (3,5-DLT), between about 30 and about 7OnM of 3,5-DLT, between about 35 and about 65nM of 3,5-DLT, between about 40 and about 6OnM of 3,5-DLT, between about 45 and about 55nM of 3,5-DLT, or about 5OnM of 3,5-DLT.
  • 3,5-diiodo-L-thyronine 3,5-diiodo-L-thyronine
  • a culture medium of the invention will therefore normally contain many other ingredients in addition to an FXR agonist, an RXR or RAR agonist, a PPAR agonist and/or a THR agonist. Suitable combinations of ingredients can readily be formulated by the skilled person, taking into account the following disclosure.
  • a culture medium according to the invention will generally be a nutrient solution comprising standard cell culture ingredients, such as amino acids, vitamins, inorganic salts, a carbon energy source, and a buffer, as described in more detail below.
  • a culture medium according to the invention may be generated by modification of an existing cell culture medium.
  • the skilled person understands the types of culture media that might be used for pluripotent stem cell culture. Potentially suitable cell culture media are available commercially, and include Dulbecco's Modified Eagle Media (DMEM), Minimal Essential Medium (MEM), Knockout-DMEM (KO-DMEM), Glasgow Minimal Essential Medium (G-MEM), Basal Medium Eagle (BME), DMEM/Ham's F 12, Advanced DMEM/Ham's F 12, Iscove's Modified Dulbecco's Media and Minimal Essential Media (MEM).
  • a culture medium for use in the invention may comprise one or more amino acids.
  • Amino acids which may be present include L-alanine, L- arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L- glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine and combinations thereof.
  • each amino acid when present is present at about 0.001 to about 1 g/L of medium (usually at about 0.01 to about 0.15 g/L), except for L-glutamine which is present at about 0.05 to about 1 g/L (usually about 0.1 to about 0.75 g/L).
  • the amino acids may be of synthetic origin.
  • a culture medium for use in the invention may comprise one or more vitamins.
  • Vitamins which may be present include thiamine (vitamin Bl), riboflavin (vitamin B2), niacin (vitamin B3), D-calcium pantothenate (vitamin B5), pyridoxal/pyridoxamine/pyridoxine (vitamin B6), folic acid (vitamin B9), cyanocobalamin (vitamin B 12), ascorbic acid (vitamin C), calciferol (vitamin D2), DL- alpha tocopherol (vitamin E), biotin (vitamin H) and menadione (vitamin K).
  • a culture medium for use in the invention may comprise one or more inorganic salts.
  • inorganic salts are typically included in culture media to aid maintenance of the osmotic balance of the cells and to help regulate membrane potential.
  • Inorganic salts which may be present include salts of calcium, copper, iron, magnesium, potassium, sodium, zinc. The salts are normally used in the form of chlorides, phosphates, sulphates, nitrates and bicarbonates.
  • Specific salts that may be used include CaCl 2 , CuSO 4 -5H 2 O, Fe(NO 3 )-9H 2 O, FeSO 4 -7H 2 O, MgCl, MgSO 4 , KCl, NaHCO 3 , NaCl, Na 2 HPO 4 , Na 2 HPO 4 -H 2 O and ZnSO 4 -7H 2 O.
  • the osmolarity of the medium may be in the range from about 200 to about 400 m ⁇ sm/kg, in the range from about 290 to about 350 m ⁇ sm/kg, or in the range from about 280 to about 310 m ⁇ sm/kg.
  • the osmolarity of the medium may be less than about 300 m ⁇ sm/kg (e.g. about 280 m ⁇ sm/kg).
  • a culture medium for use in the invention may comprise a carbon energy source, in the form of one or more sugars.
  • a carbon energy source in the form of one or more sugars.
  • Sugars which may be present include glucose, galactose, maltose and fructose.
  • the sugar is preferably glucose, particularly D-glucose (dextrose).
  • a carbon energy source will normally be present at between about 1 and about 10 g/L.
  • a culture medium for use in the invention may comprise a buffer.
  • a suitable buffer can readily be selected by the skilled person.
  • the buffer may be capable of maintaining the pH of the culture medium in the range about 6.5 to about 7.5 during normal culturing conditions, most preferably around pH 7.0.
  • Buffers that may be used include carbonates (e.g. NaHCO 3 ), chlorides (e.g. CaCl 2 ), sulphates (e.g. MgSO 4 ) and phosphates (e.g. NaH 2 PO 4 ). These buffers are generally used at about 50 to about 500 mg/1.
  • buffers such as N-[2-hydroxyethyl]-piperazine-N'-[2-ethanesul-phonic acid] (HEPES) and 3-[N- morpholinoj-propanesulfonic acid (MOPS) may also be used, normally at around 1000 to around 10,000 mg/1.
  • a culture medium of the invention may contain serum. Serum obtained from any appropriate source may be used, including fetal bovine serum (FBS), goat serum or human serum. Preferably, human serum is used. Serum may be used at between about 1% and about 30% by volume of the medium, according to conventional techniques.
  • FBS fetal bovine serum
  • human serum is used. Serum may be used at between about 1% and about 30% by volume of the medium, according to conventional techniques.
  • a culture medium of the invention may contain a serum replacement.
  • a serum replacement Various different serum replacement formulations are commercially available and are known to the skilled person. Where a serum replacement is used, it may be used at between about 1% and about 30% by volume of the medium, according to conventional techniques.
  • a culture medium of the invention may be serum-free and/or serum replacement-free.
  • a serum-free medium is one that contains no animal serum of any type. Serum-free media may be preferred to avoid possible xeno-contamination of the stem cells.
  • a serum replacement-free medium is one that has not been supplemented with any commercial serum replacement formulation.
  • a culture medium may comprise cholesterol or a cholesterol substitute.
  • Cholesterol may be provided in the form of the HDL or LDL extract of serum. Where the HDL or LDL extract of serum is used, it is preferably the extract of human serum.
  • the optimal amount of cholesterol or cholesterol substitute can readily be determined from the literature or by routine experimentation.
  • a synthetic cholesterol substitute may be used rather than cholesterol derived from an animal source. For example, SynthecolTM (Sigma S5442) may be used in accordance with the manufacturer's instructions.
  • the culture medium may further comprise transferrin or a transferrin substitute.
  • Transferrin may be provided in the form of recombinant transferrin or in the form of an extract from serum.
  • recombinant human transferrin or an extract of human serum is used.
  • An iron chelate compound may be used as a transferrin substitute. Suitable iron chelate compounds are known to those of skill in the art, and include ferric citrate chelates and ferric sulphate chelates. The optimal amount of transferrin or transferrin substitute can readily be determined from the literature or by routine experimentation.
  • a culture medium of the invention may comprise transferrin at about 5.5 ⁇ g/ml.
  • the culture medium may further comprise albumin or an albumin substitute, such as bovine serum albumin (BSA), human serum albumin (HSA), a plant hydrolysate (e.g. a rice or soy hydrolysate), Albumax® I or Albumax® II.
  • BSA bovine serum albumin
  • HSA human serum albumin
  • a plant hydrolysate e.g. a rice or soy hydrolysate
  • Albumax® I or Albumax® II e.g. a rice or soy hydrolysate
  • albumin substitute such as bovine serum albumin (BSA), human serum albumin (HSA), a plant hydrolysate (e.g. a rice or soy hydrolysate), Albumax® I or Albumax® II.
  • the optimal amount of albumin or albumin substitute can readily be determined from the literature or by routine experimentation.
  • a culture medium of the invention may comprise albumin at about 0.5 ⁇ g/ml.
  • the culture medium may further comprise insulin or an insulin substitute. Natural or recombinant insulin may be used.
  • a zinc-containing compound may be used as an insulin substitute, e.g. zinc chloride, zinc nitrate, zinc bromide or zinc sulphate.
  • the optimal amount of insulin or insulin substitute can readily be determined from the literature or by routine experimentation.
  • a culture medium of the invention may comprise insulin at about 1 O ⁇ g/ml.
  • the culture medium may comprise progesterone, putrescine, and/or selenite. If selenite is present, it is preferably in the form of sodium selenite. The optimal amount of these ingredients can readily be determined from the literature or by routine experimentation.
  • a culture medium of the invention may comprise one or more additional nutrients or growth factors that have previously been reported to benefit pluripotent stem cell culture.
  • a culture medium may comprise fibroblast growth factor (FGF), transforming growth factor beta 1 (TGFp 1 ), leukemia inhibitor factor (LIF), ciliary neurotrophic factor (CNTF), interleukin 6 (IL-6) or stem cell factor (SCF).
  • FGF fibroblast growth factor
  • TGFp 1 transforming growth factor beta 1
  • LIF leukemia inhibitor factor
  • CNTF ciliary neurotrophic factor
  • IL-6 interleukin 6
  • SCF stem cell factor
  • Antibodies or other ligands that bind to the receptors for such substances may also be used.
  • Any form of FGF suitable for pluripotent stem cell culture may be used, e.g. basic FGF (bFGF; FGF-2), FGF-4, or homologs or analogs thereof.
  • bFGF is used.
  • bFGF may be used at from about
  • a culture medium for use in the invention may comprise one or more trace elements, such as ions of barium, bromium, cobalt, iodine, manganese, cliromium, copper, nickel, selenium, vanadium, titanium, germanium, molybdenum, silicon, iron, fluorine, silver, rubidium, tin, zirconium, cadmium, zinc and/or aluminium.
  • trace elements such as ions of barium, bromium, cobalt, iodine, manganese, cliromium, copper, nickel, selenium, vanadium, titanium, germanium, molybdenum, silicon, iron, fluorine, silver, rubidium, tin, zirconium, cadmium, zinc and/or aluminium.
  • a culture medium may further comprise phenol red as a pH indicator, to enable the status of the medium to be easily monitored (e.g. at about 5 to about 50 mg/litre).
  • the medium may comprise a reducing agent, such as ⁇ -mercaptoethanol at a concentration of about 0.1 mM.
  • a reducing agent such as ⁇ -mercaptoethanol at a concentration of about 0.1 mM.
  • a culture medium of the invention comprises a bile acid, a retinol and a diiodothyronine.
  • a culture medium may comprise cholic acid, all-trans-retinol (ATR) and 3,5-diiodo-L-thyronine.
  • a culture medium may comprise cholic acid, all-trans-retinol, 3,5-diiodo-L-thyronine, cholesterol, transferrin, L-glutamine, progesterone, putrescine, insulin, selenite and DL-alpha-tocopherol (vitamin E).
  • a culture medium may comprise transferrin, insulin, progesterone, putrescine, and sodium selenite.
  • 'N2 Supplement' (available from Invitrogen, Carlsbad, CA; www.invitiOgen.com; catalog no. 17502-048; and from PAA Laboratories GmbH, Pasching, Austria; www.paa.com; catalog no. F005-004; Bottenstein & Sato, PNAS, 76(1):514-517, 1979) may be used to formulate a culture medium that comprises contains transferrin, insulin, progesterone, putrescine, and sodium selenite.
  • N2 Supplement is supplied by PAA Laboratories GmbH as a 10Ox liquid concentrate, containing 500 ⁇ g/ml human transferrin, 500 ⁇ g/ml bovine insulin, 0.63 ⁇ g/ml progesterone, 1611 ⁇ g/ml putrescine, and 0.52 ⁇ g/ml sodium selenite.
  • N2 Supplement may be added to a culture medium as a concentrate or diluted before addition to a culture medium. It may be used at a Ix final concentration or at other final concentrations.
  • Use of N2 Supplement is a convenient way to incorporate transferrin, insulin, progesterone, putrescine and sodium selenite into a culture medium of the invention.
  • the invention provides a culture medium as described herein for expanding a population of pluripotent stem cells, which comprises transferrin, insulin, progesterone, putrescine, and sodium selenite (optionally comprising N2 Supplement).
  • the invention also provides a method as described herein for preparing a culture medium, which comprises adding transferrin, insulin, progesterone, putrescine, and sodium selenite to a culture medium (optionally by supplementing the medium with N2 Supplement).
  • a culture medium may comprise biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri- iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • F01-002; Brewer et al, J Neurosci Res., 35(5):567-76, 1993) may be used to formulate a culture medium that comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, triiodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • a culture medium that comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, triiodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • B27 Supplement is supplied by PAA Laboratories GmbH as a liquid 5Ox concentrate, containing amongst other ingredients biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin. Of these ingredients at least linolenic acid, retinol, retinyl acetate and tri-iodothyronine (T3) are nuclear hormone receptor agonists as described elsewhere herein.
  • B27 Supplement may be added to a culture medium as a concentrate or diluted before addition to a culture medium. It may be used at a Ix final concentration or at other final concentrations.
  • Use of B27 Supplement is a convenient way to incorporate biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri- iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin into a culture medium of the invention.
  • the invention provides a culture medium as described herein for expanding a population of pluripotent stem cells, which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, triiodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin (optionally comprising B27 Supplement).
  • a culture medium as described herein for expanding a population of pluripotent stem cells which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, triiodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin (optionally comprising B27 Supplement).
  • the invention also provides a method as described herein for preparing a culture medium, which comprises adding biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin to a culture medium (optionally by supplementing the medium with B27 Supplement).
  • a method as described herein for preparing a culture medium which comprises adding biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin to a culture medium (optionally by supplementing the medium with B
  • N2 Supplement and B27 Supplement may be used in combination in a culture medium of the invention (see Example 5 herein).
  • the invention therefore also provides a culture medium as described herein for expanding a population of pluripotent stem cells, which has been supplemented with N2 Supplement and B27 Supplement.
  • the invention also provides a method as described herein for preparing a culture medium, which comprises adding N2 Supplement and B27 Supplement to a culture medium.
  • a culture medium of the invention will normally be formulated in deionized, distilled water.
  • a culture medium of the invention will typically be sterilized prior to use to prevent contamination, e.g. by ultraviolet light, heating, irradiation or filtration.
  • the culture medium may be frozen (e.g. at -20 0 C or -80 0 C) for storage or transport.
  • the medium may contain one or more antibiotics to prevent contamination.
  • the medium may have an endotoxin content of less that 0.1 endotoxin units per ml, or may have an endotoxin content less than 0.05 endotoxin units per ml. Methods for determining the endotoxin content of culture media are known in the art.
  • the culture medium is a conditioned medium.
  • Conditioned medium is produced by culturing a population (typically of non-pluripotent) cells in a culture medium for a time sufficient to condition the medium, then harvesting the conditioned medium.
  • Conditioned medium contains growth factors, cytokines and other nutrients secreted by the conditioning cells that support growth of stem cells.
  • the medium comprises conditioned VitroHES (VitroLife AB, Sweden).
  • the medium may be conditioned on mammalian cells, e.g. mouse cells or human cells.
  • mammalian cells e.g. mouse cells or human cells.
  • Various different types of mammalian cells may be used to produce conditioned medium suitable for pluripotent stem cell culture, including mouse embryonic fibroblasts (mEF), human foreskin cells and human fallopian epithelial cells.
  • mEF cells are used.
  • Conditioned medium may be prepared by well known methods, e.g. by culturing mEFs and harvesting the culture medium after an appropriate time ⁇ e.g. ⁇ 1 day at 37°C).
  • the cells used to condition a medium may be irradiated or treated with a substance ⁇ e.g. mitomycin C) to prevent their proliferation.
  • An appropriate culturing time to condition a medium may be estimated by the skilled person, based on known methods. Alternatively, the time required to condition the medium can be determined by assessing the effect of the conditioned medium on pluripotent stem cell growth and differentiation. The conditioning time can be altered after assessing the effect of the conditioned medium on stem cell growth and differentiation. Typically, a medium will be conditioned for between about 1 and about 72 hours, such as between about 4 hours and about 48 hours, or between about 4 hours and about 24 hours, at 37 0 C.
  • the period over which a conditioned medium can support pluripotent stem cell expansion may likewise be estimated by the skilled person, based on known methods, or may be assessed experimentally.
  • the period before replacement or exchange of conditioned medium can therefore be altered after assessing the effect of a conditioned medium on stem cell growth and differentiation.
  • Conditioned medium is typically used to support cell growth for between about 6 hours and about 72 hours, such as between about 12 hours and about 56 hours, e.g. for about 24-36 hours or for about 24-48 hours, before replacement or exchange with a further batch of conditioned medium.
  • the culture medium is a fresh culture medium.
  • a fresh medium is a medium that has not been conditioned.
  • a fresh medium may be preferred, because such a medium may be chemically defined (i.e. all of the ingredients in the medium and their concentrations may be known), in contrast to a conditioned medium (which is not fully defined because the conditioning cells alter the composition of the medium, and because of batch- to-batch variations).
  • the culture medium is a mixture of a fresh medium and a conditioned medium.
  • the conditioned medium and the fresh medium may be of the same type or may be of different types.
  • the combination of ingredients in the conditioned medium prior to conditioning is different to the combination of ingredients in the fresh medium (e.g. the conditioned medium may be conditioned VitroHES and the fresh medium may be DMEM/F12).
  • the mixed culture medium is not one that would be obtained by merely diluting a concentrated medium with an non- concentrated or diluted form of the same medium, nor is it one that would be obtained by adding to a conditioned medium more fresh medium of the same type.
  • the invention provides a method for preparing a mixed culture medium for expanding a population of pluripotent stem cells, comprising: (a) providing a conditioned medium; (b) providing a fresh medium; and (c) mixing at least part of the conditioned medium with at least part of the fresh medium, thereby forming a mixed culture medium, wherein the conditioned medium and the fresh medium are of different types.
  • the invention also provides methods, compositions and uses as described herein involving such mixed culture media.
  • the culture medium of the invention is a mixture of a conditioned medium and a fresh medium of different types, which comprises a bile acid, a retinol and a diiodothyronine.
  • the culture medium of the invention is a mixture of a conditioned medium and a fresh medium of different types, which comprises cholic acid, all-trans-retinol and 3,5-diiodo-L-thyronine.
  • a culture medium of the invention is a mixture of a conditioned medium and a fresh medium, which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri- iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • B27 Supplement available from Invitrogen, Carlsbad, CA; www.invitrogen.com; currently catalog no. 17504-044; and from PAA Laboratories GmbH, Pasching, Austria; www.paa.com: catalog no.
  • B27 Supplement is a convenient way to incorporate biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin into a culture medium of the invention.
  • use of N2 Supplement is a convenient way to incorporate transferrin, insulin, progesterone, putrescine and sodium selenite into a culture medium of the invention.
  • a culture medium of the invention is a mixture of a conditioned medium and a fresh medium, which has been supplemented with B27 Supplement and N2 Supplement.
  • a culture medium of the invention is a mixture of a conditioned medium and a fresh medium of different types, which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • a culture medium of the invention is a mixture of a conditioned medium and a fresh medium of different types, which has been supplemented with B27 Supplement and N2 Supplement.
  • the fresh medium may be DMEM/F12 (Invitrogen).
  • the conditioned medium may be VitrohES (Vitrolife AB) conditioned on mouse embryonic fibroblast cells.
  • the invention provides a culture medium comprising a mixture of mEF-conditioned VitrohES and fresh DMEM/F12, which has been supplemented with B27 Supplement and N2 Supplement.
  • a conditioned medium is mixed with a fresh medium
  • the conditioned medium and fresh medium may be mixed to form a mixed culture medium that comprises at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%, by volume (or by dry weight) conditioned medium.
  • a conditioned medium is mixed with a fresh medium
  • the conditioned medium and fresh medium may be mixed to form a mixed culture medium that comprises at least 5%, at least 10%, at least 15%, at least 20% 5 . at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%, by volume (or by dry weight) fresh medium.
  • a culture medium may be a Ix formulation or a concentrated formulation, e.g. a 2x to 25Ox concentrated medium formulation.
  • a Ix formulation each ingredient in the medium is at the concentration intended for cell culture.
  • a concentrated formulation one or more of the ingredients is present at a higher concentration than intended for cell culture.
  • Concentrated culture media is well known in the art. Culture media can be concentrated using known methods e.g. salt precipitation or selective filtration.
  • a concentrated medium may be diluted for use with water (preferably deionized and distilled) or any appropriate solution, e.g. an aqueous saline solution, an aqueous buffer or a culture medium.
  • agonists to FXR, RXR, RAR, PPAR and THR may activate complex nuclear signalling pathways that inhibit differentiation of stem cells and allow them to rapidly proliferate whilst maintaining their pluripotency.
  • a culture medium as disclosed herein may be capable of expanding a population of stem cells in a pluripotent, undifferentiated and proliferative state for at least 3 passages under appropriate conditions.
  • Stem cells are considered to be in a pluripotent, undifferentiated and proliferative state if they exhibit certain characteristics as described in more detail elsewhere herein.
  • Appropriate conditions can be selected by the skilled person from those normally used for pluripotent stem cell culture.
  • a culture medium is capable of expanding a population of stem cells in a pluripotent, undifferentiated and proliferative state for at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100, passages under appropriate conditions.
  • a culture medium may be capable of expanding a population of pluripotent stem cells in a pluripotent, undifferentiated and proliferative state for more than 3 passages, more than 4 passages, more than 5 passages, more than 10 passages, more than 15 passages, more than 20 passages, more than 25 passages, more than 30 passages, more than 40 passages, more than 50 passages, or more than 100 passages.
  • the stem cells are cultured in a pluripotent, undifferentiated and proliferative state for at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100, passages under appropriate conditions.
  • a culture medium as disclosed herein may be capable of expanding at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 different pluripotent stem cell lines (e.g. different human ESC lines) in a pluripotent, undifferentiated and proliferative state for multiple passages under appropriate conditions.
  • a culture medium may be capable of expanding at least the SA121, SA181 and SA461 hES cell lines (see elsewhere herein) in a pluripotent, undifferentiated and proliferative state for at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10, passages under appropriate conditions.
  • the invention also provides a hermetically-sealed vessel containing a culture medium of the invention.
  • Hermetically-sealed vessels may be preferred for transport or storage of the culture media, to prevent contamination.
  • the vessel may be any suitable vessel, such as a flask, a plate, a bottle, ajar, a vial or a bag.
  • the invention also provides a method for preparing a culture medium, comprising the steps of: (a) obtaining a culture medium; and (b) adding a farnesoid X receptor (FXR) agonist, a retinoid X receptor (RXR) or retinoic acid receptor (RAR) agonist, a peroxisome proliferator-activated receptor (PPAR) agonist, and/or a thyroid hormone receptor (THR) agonist to the culture medium.
  • FXR farnesoid X receptor
  • RXR retinoid X receptor
  • RAR retinoic acid receptor
  • PPAR peroxisome proliferator-activated receptor
  • TTR thyroid hormone receptor
  • a method for preparing a culture medium may comprise the steps of: (a) obtaining a culture medium; and (b) adding a bile acid, a retinol and a diiodothyronine to the culture medium.
  • a method for preparing a culture medium may comprise the steps of: (a) obtaining a culture medium; and (b) adding cholic acid, all-trans-retinol and 3,5-diiodo- L-thyronine to the culture medium.
  • the culture medium may be a conditioned medium, or a mixture of a conditioned medium and a fresh medium of different types, as described elsewhere herein.
  • the culture media of the invention can be used to expand a population of pluripotent stem cells. Accordingly, the invention provides the use of any culture medium as disclosed herein for expanding a population of pluripotent stem cells.
  • the invention also provides a method for expanding a population of pluripotent stem cells, comprising: (a) providing a population of pluripotent stem cells; (b) providing a culture medium as disclosed herein; (c) contacting the stem cells with the culture medium; and (d) culturing the stem cells under appropriate conditions.
  • a method for 'expanding' a population of cells is one that involves increasing the number of stem cells in an initial population to generate an expanded population, whilst maintaining pluripotency and without significant differentiation, i.e. one that involves growth and division of stem cells, but not their differentiation.
  • the methods of the invention may comprise culturing the cells in contact with an extracellular matrix material as described elsewhere herein.
  • the invention provides a method for expanding a population of pluripotent stem cells, comprising: (a) providing a population of pluripotent stem cells; (b) providing a culture medium as disclosed herein; (c) contacting the stem cells with the culture medium; and (d) culturing the cells under appropriate conditions and in contact with an extracellular matrix material.
  • the invention also provides the use of a culture medium as disclosed herein and an extracellular matrix material to expand a population of pluripotent stem cells.
  • the methods of the invention may comprise a step of passaging stem cells into a culture medium as disclosed herein.
  • the invention provides a method for expanding a population of pluripotent stem cells, comprising: (a) providing a population of pluripotent stem cells; (b) providing a culture medium as disclosed herein; (c) contacting the stem cells with the culture medium; (d) culturing the cells under appropriate conditions; (e) passaging the cells into a culture medium as disclosed herein; and (f) further culturing the cells under appropriate conditions.
  • the steps of the methods disclosed herein can be performed in any suitable order or at the same time, as appropriate, and need not be performed in the order in which they are listed.
  • the step of providing a population of pluripotent stem cells may be performed before, after or at the same time as, the step of providing a culture medium.
  • Cells may be passaged in the methods of the invention using known methods, e.g. by incubating the cells with trypsin and EDTA for between 5 seconds and 15 minutes at 37°C.
  • a trypsin substitute e.g. TrypLE from Invitrogen
  • Collagenase, dispase, accutase or other known reagents may also be used to passage the cells. Passaging is typically required every 2-8 days, such as every 4-7 days, depending on the initial seeding density.
  • the cell culture methods of the invention do not comprise any step of manually selecting undifferentiated cells when the cells are passaged.
  • the cell culture methods of the invention comprise automated passaging of the stem cells, i.e. without manipulation by a laboratory worker.
  • the pluripotent stem cells will be seeded onto a support at a density that promotes cell proliferation but which limits differentiation. Typically, a plating density of at least 15,000 cells/cm 2 is used. A plating density of between about 15,000 cells/cm 2 and about 200,000 cells/cm 2 may be used. Single-cell suspensions or small cluster of cells will normally be seeded, rather than large clusters of cells, as in known in the art.
  • the environment used to culture the stem cells may be sterile and temperature stable.
  • the culture media disclosed herein are particularly advantageous because they can be used to expand pluripotent stem cells without the need to adapt the cells to the culture medium, as is commonly required when transferring stem cells into a new culture medium.
  • Various different methods for adapting cell cultures to new media are known in the art. Accordingly, in some embodiments the methods of the invention do not include any step of adapting a population of stem cells to a new culture medium, e.g. by gradually changing the components of the medium.
  • the invention therefore provides a method for expanding a population of pluripotent stem cells, comprising: (a) providing a population of pluripotent stem cells; (b) providing a first culture medium; (c) culturing the cells in the first culture medium under appropriate conditions; (d) providing a second culture medium, which is a culture medium as disclosed herein, and which is different to the first culture medium; (e) replacing the first culture medium with the second culture medium, exchanging the first culture medium with the second culture medium or passaging the cells from the first culture medium into the second culture medium; and (f) further culturing the cells in the second culture medium under appropriate conditions, wherein the method does not comprise any step of adapting the population of stem cells to the second culture medium.
  • the methods and uses of the invention may involve any culture medium or supplement as described herein. Accordingly, in some embodiments the methods of the invention may be serum and/or serum replacement-free methods. In some embodiments, the methods of the invention may be used to culture cells in the absence of contact with a layer of feeder cells.
  • the methods of the invention may be performed using any suitable cell culture vessel as a support.
  • Cell culture vessels of various shapes and sizes ⁇ e.g. flasks, single or multiwell plates, single or multiwell dishes, bottles, jars, vials, bags, bioreactors) and constructed from various different materials (e.g. plastic, glass) are known in the art.
  • a suitable cell culture vessel can readily be selected by the skilled person.
  • the invention also provides a culture medium supplement that can be used to produce a culture medium as disclosed herein.
  • a "culture medium supplement' is a mixture of ingredients that cannot itself support pluripotent stem cells, but which enables or improves pluripotent stem cell culture when combined with other cell culture ingredients.
  • the supplement can therefore be used to produce a functional cell culture medium of the invention by combining it with other cell culture ingredients to produce an appropriate medium formulation.
  • the use of culture medium supplements is well known in the art.
  • the invention provides a culture medium supplement that comprises a farnesoid X receptor (FXR) agonist, a retinoid X receptor (RXR) or retinoic acid receptor (RAR) agonist, a peroxisome proliferator-activated receptor (PPAR) agonist, and/or a thyroid hormone receptor (THR) agonist.
  • the supplement may contain any agonist (or combination of agonists) disclosed herein.
  • the supplement may also contain one or more additional cell culture ingredients as disclosed herein, e.g. one or more cell culture ingredients selected from the group consisting of amino acids, vitamins, inorganic salts, carbon energy sources and buffers.
  • a culture medium supplement may be a concentrated liquid supplement (e.g. a 2x to 25Ox concentrated liquid supplement) or may be a dry supplement. Both liquid and dry supplements are well known in the art.
  • a supplement may be lyophilised.
  • a supplement of the invention will typically be sterilized prior to use to prevent contamination, e.g. by ultraviolet light, heating, irradiation or filtration.
  • a culture medium supplement may be frozen (e.g. at -20°C or -80°C) for storage or transport.
  • the invention also provides a hermetically- sealed vessel containing a culture medium supplement of the invention.
  • Hermetically-sealed vessels may be preferred for transport or storage of the culture media supplements disclosed herein, to prevent contamination.
  • the vessel may be any suitable vessel, such as a flask, a plate, a bottle, ajar, a vial or a bag.
  • the cell culture media and cell culture supplements disclosed herein can be used to expand a population of pluripotent stem cells. Accordingly, the invention provides compositions arising during use of the cell culture media and cell culture supplements of the invention. For example, the invention provides a composition comprising: (a) a culture medium according to the invention; and (b) pluripotent stem cells.
  • Feeder cell layers are often used to support the culture of pluripotent stem cells, and to inhibit their differentiation.
  • a feeder cell layer is generally a monolayer of cells that is co-cultured with, and which provides a surface suitable for growth of, the pluripotent cells of interest.
  • the feeder cell layer provides an environment in which the cells of interest can grow.
  • Feeder cells are often mitotically inactivated (e.g. by irradiation or treatment with mitomycin C) to prevent their proliferation.
  • the culture media of the invention are particularly advantageous because they can be used to culture cells without feeder cell contact, i. e. the methods of the invention do not require a layer of feeder cells to support the stem cells.
  • compositions of the invention may be feeder cell-free compositions.
  • a composition is conventionally considered to be feeder cell-free if the pluripotent stem cells in the composition have been cultured for at least one passage in the absence of a feeder cell layer.
  • a feeder cell-free composition of the invention will normally contain less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% feeder cells (expressed as a % of the total number of cells in the composition).
  • An extracellular matrix material may be used to substitute the supportive function of a feeder cell layer.
  • the invention therefore also provides a composition containing: (a) a culture medium according to the invention; and (b) an extracellular matrix material. These compositions may further comprise pluripotent stem cells.
  • An extracellular matrix material may comprise f ⁇ bronectin, vitronectin, laminin, collagen (particularly collagen II, collagen III or collagen IV), thrombospondin, osteonectin, secreted phosphoprotein I 5 heparan sulphate, dermatan sulphate, gelatine, merosin, tenasin, decorin, entactin or a basement membrane preparation from Engelbreth-Ho Im-S warm (EHS) mouse sarcoma cells (e.g. Matrigel®; Becton Dickenson).
  • EHS Engelbreth-Ho Im-S warm
  • a synthetic extracellular matrix material such as ProNectin (Sigma Z378666) may be used. Mixtures of extracellular matrix materials may be used, if desired.
  • the extracellular matrix material comprises fibronectin.
  • Bovine fibronectin, recombinant bovine fibronectin, human fibronectin, recombinant human fibronectin, mouse fibronectin, recombinant mouse fibronectin or synthetic fibronectin may be used.
  • the extracellular matrix material will normally be coated onto a cell culture vessel, but may (in addition or alternatively) be supplied in solution.
  • a fibronectin solution of about lmg/ml may be used to coat a cell culture vessel.
  • a cell culture vessel is coated with fibronectin at about 1 ⁇ g/cm 2 to about 250 ⁇ g/cm 2 , or at about 1 ⁇ g/cm to about 150 ⁇ g/cm .
  • a cell culture vessel is coated with fibronectin at 8 ⁇ g/cm 2 or 125 ⁇ g/cm 2 .
  • the invention also provides the use of (a) an extracellular matrix material; and (b) a famesoid X receptor (FXR) agonist, a retinoid X receptor (RXR) or retinoic acid receptor (RAR) agonist, a peroxisome proliferator-activated receptor (PPAR) agonist, and/or a thyroid hormone receptor (THR) agonist, for expanding a population of pluripotent stem cells.
  • FXR famesoid X receptor
  • RXR retinoid X receptor
  • RAR retinoic acid receptor
  • PPAR peroxisome proliferator-activated receptor
  • TMR thyroid hormone receptor
  • the invention provides the use of fibronectin, cholic acid, all-trans-retinol and 3,5-diiodo-L-thyronine for expanding a population of pluripotent stem cells.
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a farnesoid X receptor (FXR) agonist, a retinoid X receptor (RXR) or retinoic acid receptor (RAR) agonist, a peroxisome proliferator- activated receptor (PPAR) agonist, and/or a thyroid hormone receptor (THR) agonist.
  • FXR farnesoid X receptor
  • RXR retinoid X receptor
  • RAR retinoic acid receptor
  • PPAR peroxisome proliferator- activated receptor
  • TTR thyroid hormone receptor
  • the invention provides a composition or cell culture vessel comprising fibronectin, cholic acid, all-trans-retinol and 3,5-diiodo-L-thyronine.
  • compositions of the invention may comprise serum, or may be serum-free and/or serum-replacement free, as described elsewhere herein.
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • a culture medium which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium which has been supplemented with B27 Supplement and N2 Supplement.
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium which is a mixture of a conditioned medium and a fresh medium, and which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • a culture medium which is a mixture of a conditioned medium and a fresh medium, and which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium which is a mixture of a conditioned medium and a fresh medium, and which has been supplemented with B27 Supplement and N2 Supplement.
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium which is a mixture of a conditioned medium and a fresh medium of different types, and which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E), albumin, insulin and transferrin.
  • a culture medium which is a mixture of a conditioned medium and a fresh medium of different types, and which comprises biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol, retinyl acetate, sodium selenite, tri-iodothyronine (T3), DL-alpha tocopherol (vitamin E
  • the invention also provides a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium which is a mixture of a conditioned medium and a fresh medium of different types, and which has been supplemented with B27 Supplement and N2 Supplement.
  • a composition or cell culture vessel comprising (a) an extracellular matrix material; and (b) a culture medium comprising a mixture of mEF-conditioned VitrohES and fresh DMEM/F12, which has been supplemented with B27 Supplement and N2 Supplement.
  • the culture media and methods disclosed herein are useful for expanding a population of pluripotent stem cells, whilst maintaining the pluripotency of the cells and without problematic differentiation of the cells.
  • 'Pluripotent' stem cells are those that have the potential to differentiate into cells of all three germ layers (endoderm, mesoderm and ectoderm) under appropriate conditions.
  • Pluripotent stem cells are not totipotent, i. e. they cannot form an entire organism, such as a foetus.
  • Pluripotent stem cells for use in the invention can be obtained using well- known methods (see below). It is envisaged that various types of pluripotent stem cells may be used in conjunction with the invention, whether obtained from embryonic, foetal or adult tissue. Stem cells may be cloned directly from an organism for use in the invention, but established stem cell lines will typically be used. Accordingly, in some embodiments the initial population of stem cells are the progeny of previously-isolated stem cells or are the progeny of an established stem cell line, such that the invention does not involve any use of a tissue sample.
  • the culture media disclosed herein may be used to culture mammalian stem cells, particularly primate embryonic stem cells.
  • Primate embryonic stem cells that may be used in conjunction with the invention include human, Rhesus monkey and marmoset embryonic stem cells.
  • Mouse embryonic stem cells may also be used.
  • the embryonic stem cells are human embryonic stem (hES) cells.
  • ES cells are prepared from the inner cell mass (ICM) of a mammalian blastocyst using known techniques.
  • human ES cells can be obtained using the methods described in Thomson et al. (1998) Science 282:1145-1147, Thomson et al. (1998) Curr. Top. Dev. Biol. 38:133 and US patent 5,843,780.
  • the initial population of cells are the progeny of previously-isolated hES cells or are the progeny of an established line of hES cells, such that the invention does not involve any use of a human embryo.
  • the initial population of hES cells are the progeny of cells or a cell line obtained using a method that did not involve any use of a human embryo.
  • hES cell lines can be used.
  • examples of commercially available stem cell lines that might be used in the invention include the SA461, SAl 21 and SAl 81 hES cell lines (Cellartis AB, G ⁇ teborg, Sweden).
  • the inventor has already successfully tested the culture media and methods of the invention with the SA461 hES cell line (see the Examples herein), and preliminary results suggest that the same culture media and methods can be used with the SAl 21 and SAl 81 hES cell lines. Accordingly, any of these cell lines can be used in the invention.
  • a culture media as disclosed herein may also be used to culture embryonic germ (EG) cells, particularly human EG cells.
  • EG cells are prepared from primordial germ cells using known techniques.
  • human EG cells can be obtained using the method described in Shamblott et al. (1998) PNAS 95:13726 and US patent 6,090,622.
  • a culture media as disclosed herein may also be used to culture genetically modified pluripotent stem cells.
  • Genetically modified cells include those that have been transiently or stably modified by transformation, transfection, transduction, etc..
  • the culture media may be used to culture GFP reporter lines, or disease models (e.g. cells containing mutations or deletions in one or more genes).
  • the culture media disclosed herein may also be used to culture cells that have been induced or transformed to form cells with ES cell-like properties.
  • pluripotent stem cells may be genetically modified cells, such as mouse or human 'induced pluripotent stem' (iPS) cells.
  • iPS cells are typically derived from adult somatic cells by transducing them with certain key pluripotency genes, in particular genes encoding transcription factors e.g. by transduction of mouse or human fibroblasts with four transcription factors: Oct-3/4, Sox2, KLF4 and c-Myc (e.g. see Takahashi et al. (2007) Cell 131(5):861-72; Yu et al (2007) Science 318(5858):1917-1920; and Yamanaka S. (2008) Cell Prolif. 41 Suppl 1 :51-6).
  • the total number of undifferentiated, pluripotent stem cells in the population will preferably increase at least 1.5 fold, at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold or at least 50 fold, between the time when a medium of the invention is applied to an initial cell population and the end of the culture period.
  • the cells may be passaged one or more times during the culture period, after which the cells may be cultured in different cell culture vessels or cells may be discarded. If cells are cultured in different cell culture vessels after passaging, or if cells are discarded during passaging, this can be taken into account when calculating the fold difference in cell numbers obtained during a known culture period.
  • a 'population' of cells is any number of cells greater than 1 , but is preferably at least IxIO 3 cells, at least IxIO 4 cells, at least IxIO 5 cells, at least IxIO 6 cells, at least IxIO 7 cells, at least IxIO 8 cells, or at least IxIO 9 cells.
  • at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95%, of the stem cells (% by cell number) in an initial cell population will be undifferentiated, pluripotent and proliferative cells.
  • Methods for identifying undifferentiated, pluripotent and proliferative stem cells, and for identifying the % of such cells in a population, are known and suitable methods for use with this invention can be selected by the skilled person depending on the stem cell type that is used.
  • Pluripotent stem cells may be identified by their ability to differentiate into cells of all three germ layers e.g. by determining the ability of the cells to differentiate into cells showing detectable expression of markers specific for all three germ layers.
  • Stem cells can be allowed to form embryoid bodies in vitro, then the embryoid bodies studied to identify cells of all three germ layers.
  • stem cells can be allowed to form teratomas in vivo ⁇ e.g. in SCID mice), then the teratomas studied to identify cells of all three germ layers.
  • At least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95%, of the stem cells in an expanded population (or in an initial population) are capable of differentiating into cells of all three germ layers in vitro or in vivo.
  • stem cells can be confirmed by karyotype analysis.
  • Stem sells can be karyotyped using known methods.
  • a normal karyotype is where all chromosomes are present ⁇ i.e. euploidy) with no noticeable alterations. Accordingly, in preferred embodiments of the invention at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95%, of the stem cells in an expanded population (or in an initial population) exhibit normal karyotypes.
  • Pluripotent stem cells may be identified via phenotypic markers.
  • Stem cell markers both intracellular and extracellular
  • hES cells may be identified via detection of hES cell markers, such as such as OCT-4, stage-specific embryonic antigen 3 (SSEA-3), stage-specific embryonic antigen 4 (SSEA-4), tumour-rejecting antigen 1- 60 (TRA- 1-60) and tumour-rejecting antigen 1-81 (TRA- 1-81).
  • At least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95%, of the stem cells in an expanded population (or in an initial population) express OCT-4, SSEA-3, SSEA-4, TRA- 1-60 and/or TRA-I -81 at levels appropriate for hES cells.
  • At least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95%, of the cells in an expanded population (or in an initial population) will (i) have the ability to differentiate into cells of all three germ layers in vitro or in vivo; (ii) exhibit normal karyotypes; and/or (iii) express the markers OCT-4, SSEA-3, SSEA-4, TRA- 1 -60 and TRA- 1 -81 at levels appropriate for hES cells.
  • Undifferentiated, pluripotent and proliferative stem cells may also be identified by their morphological characteristics. Undifferentiated, pluripotent and proliferative stem cells are readily recognisable by those of skill in the art. For example, in a normal microscope image hES cells typically have high nuclear/cytoplasmic ratios, prominent nucleoli and compact colony formation with poorly discernable cell junctions.
  • hES cells may also be identified by determining their alkaline phosphatase activity. hES cells have alkaline phosphatase activity, which can be detected by known methods.
  • references in the singular encompass the plural (e.g. "cells") unless the context requires otherwise.
  • the term “comprising” encompasses “including” as well as “consisting of e.g. a culure medium or supplement “comprising” a specific ingredient may consist exclusively of that specific ingredient or may include one or more additional substances.
  • Figure 1 illustrates the effects of some FXR agonists and antagonists on the proliferation of SA461 hES cells after 24 and 48 hours.
  • Figure 2 illustrates the effect of dihomo- ⁇ -linolenic acid on the proliferation of SA461 hES cells after 24 hours.
  • Figure 3 illustrates the effects of some THR agonists on the proliferation of SA461 hES cells after 24 and 48 hours.
  • Figure 4 illustrates the effects of some PPAR agonists on the proliferation of SA461 hES cells after 24 and 48 hours.
  • Figure 5 illustrates the effects of some RXR/RAR agonists on the proliferation of SA461 hES cells after 24 and 48 hours.
  • Figures 6-8 illustrate the typical morphology of SA461 hES cells following 6 passages in a culture system of the invention.
  • Figure 9 illustrates the normal karyotype of SA461 hES cells following 6 passages in a culture medium according to this invention.
  • Figure 10 illustrates a high alkaline phosphatase activity in SA461 hES cells following 6 passages in a culture medium according to the invention.
  • Figures 11-20 illustrate immunostaining of pluripotency markers in SA461 hES cells following 6 passages in a culture medium of the invention.
  • Figure 11 shows the results of OCT4 immunostaining on SA461 hES cells following 6 passages in a culture medium of the invention.
  • Figure 12 shows the results of DAPI staining of the SA461 hES cells of Figure 11.
  • Figure 13 shows the results of SSEA3 immunostaining on SA461 hES cells following 6 passages in a culture medium of the invention.
  • Figure 14 shows the results of DAPI staining of the SA461 hES cells of Figure 13.
  • Figure 15 shows the results of SSEA4 immunostaining on SA461 hES cells following 6 passages in a culture medium of the invention.
  • Figure 16 shows the results of DAPI staining of the SA461 hES cells of Figure 15.
  • Figure 17 shows the results of TRAl 60 immunostaining on SA461 hES cells following 6 passages in a culture medium of the invention.
  • Figure 18 shows the results of DAPI staining of the SA461 hES cells of Figure 17.
  • Figure 19 shows the results of TRAl 81 immunostaining on SA461 hES cells following 6 passages in a culture medium of the invention.
  • Figure 20 shows the results of DAPI staining of the SA461 hES cells of Figure 19.
  • Figure 21 shows an example of an expression profile of various markers of hES cell pluripotency and differentiation as measured by QRT PCR in SA461 hES cells following 6 passages in a culture medium according to this invention.
  • Figure 22 shows an example of the morphology of SA461 hES cells cultured for 4 passages in a culture medium containing dihomo- ⁇ -linolenic acid and 3,5-diiodo-L- thyronine (3,5-DLT).
  • Figure 23 shows an example of the morphology of SA461 hES cells cultured for 4 passages in media containing dihomo- ⁇ -linolenic acid, 3,5-diiodo-L-thyronine (3,5- DLT), all-trans-retinol and retinyl acetate.
  • Figure 24 shows an example of the morphology of SA461 hES cells cultured for 4 passages in media without exogenous lipid or NHR agonists.
  • Figure 25 shows an example of the morphology of SA461 hES cells cultured for 4 passages in media containing 3,5-diiodo-L-thyronine (3,5-DLT) and all-trans-retinol.
  • Figure 26 shows an example of the morphology of SA461 hES cells cultured for 4 passages in media containing all-trans-retinol, 3,5-diiodo-L-thyronine (3,5-DLT) and cholic acid (CA).
  • Figure 27 shows the results of OCT4 immunostaining on SA461 hES cells following 3 enzymatic passages in a culture medium as described in Example 5.
  • Figure 28 shows the results of DAPI staining of the SA461 hES cells of Figure 27.
  • Figure 29 illustrates the typical morphology of SA461 hES cells following 3 enzymatic passages in a culture system as described in Example 5.
  • Figure 30 shows the results of smooth muscle actin immunostaining on differentiated cells derived from SA461 hES cells following 3 enzymatic passages in a culture medium as described in Example 5.
  • Figure 31 shows the results of DAPI staining of the cells of Figure 30.
  • Figure 32 shows the results of beta tubulin immunostaining on differentiated cells derived from SA461 hES cells following 3 enzymatic passages in a culture medium as described in Example 5.
  • Figure 33 shows the results of DAPI staining of the cells of Figure 32.
  • Figure 34 shows the results of HNF3 ⁇ immunostaining on differentiated cells derived from SA461 hES cells following 3 enzymatic passages in a culture medium as described in Example 5.
  • Figure 35 shows the results of DAPI staining of the cells of Figure 34.
  • Figure 36 shows the results of in vivo differentiation of SA121 hES cells to tissue representative of all three germ layers following 23 passages in a culture medium as described in Example 5.
  • Figure 37 shows the results of in vivo differentiation of SA461 hES cells to tissue representative of all three germ layers following 17 passages in a culture medium as described in Example 5.
  • the following examples are provided to illustrate the invention, and do not limit the scope of the preceding description or the following claims.
  • the culture media and methods described in the examples herein were designed primarily for hES cell expansion, and may be adapted for use with other types of pluripotent stem cells by routine optimisation without undue experimentation.
  • NHRs Nuclear hormone receptors
  • NHRs are known to influence cell growth and differentiation in other cell types, have widely varying effects dependant on different patterns of receptor dimerisation and are present in serum.
  • Agonists that have been investigated include agonists for the FXR, the RXR and RAR, the PPAR, and the THR.
  • the hES cells used in these experiments were line SA461 from human blastocysts established by Cellartis AB (Goteborg, Sweden). For these assays this cell line was dissociated to single cells and plated in a 96 well format before culture in a basal medium to determine the activity of the various ligands without the interference or masking effect of exogenous growth factors or conditioned medium.
  • the proliferation inducing ability was established by comparison with control wells using a proliferation assay based on the activity of cellular mitochondrial dehydrogenases, a measurment directly proportional to cell number. The lack of washing or harvesting steps in this assay removes the possibility of cell loss during processing.
  • SA461 stem cells at passage 74 were treated with Y27632 (Calbiochem) for 4 hours then trypsinised and seeded as a single cell suspension in VitrohES (Vitrolife AB) with 1 O ⁇ M Y27632 in 96 well plate format on a fibronectin coated surface (16.6 ⁇ g/cm 2 ) at a density of 10,000 cells/well.
  • VitrohES Vitrolife AB
  • 1 O ⁇ M Y27632 in 96 well plate format on a fibronectin coated surface (16.6 ⁇ g/cm 2 ) at a density of 10,000 cells/well.
  • the cell culture medium was changed 24 hours after attachment to Advanced DMEM/F12 (Invitrogen) and agonist or antagonist added. Each compound was resuspended in DMSO as a 1OmM stock solution prior to addition to the culture medium.
  • FXR agonists and antagonists were tested: cholic acid (CA), deoxycholic acid (DCA), taurodeoxycholic acid (TDCA), lithocholic acid (LCA) and Z- Guggulsterone (Z-G) (all Biomol).
  • CA cholic acid
  • DCA deoxycholic acid
  • TDCA taurodeoxycholic acid
  • LCA lithocholic acid
  • Z-G Z- Guggulsterone
  • THR agonists were tested: 3,5-diiodo-L-thyronine (3,5-DLT), 3,5-diiodo- L-tyrosine dihydrate (DLTdH) and 3,5-diiodo-4-hydroxyphenylpropionic acid (DIHPA, also sometimes referred to as DHPPA) (all Biomol).
  • PPAR agonists and antagonists were tested: 5,8,11,14-eicosatetraynoic acid, bezafibrate, clofibric acid, gemfibrozil, WYl 4643 and tetradecylthio acetic acid (all Biomol).
  • RXR and RAR agonists were tested: 13-cis retinoic acid (13cRA), 9-cis retinoic acid (9cRA), methoprene acid (MPA), 13-cis retinol (13cROL), retinyl acetate (RETACT), acitretin (ACT), 4-hydroxyretinoic acid (4HRA) and all trans retinol (ATR) (all Biomol) resuspended in DMSO.
  • Figures 1-5 show that in the case of the FXR both bile acids (cholesterol metabolites) and dihomo- ⁇ -linolenic acid (a polyunsaturated fatty acid) were able to markedly increase cell growth rates over a 48 hour timescale.
  • the importance of FXR activity in liES cell self-renewal is further demonstrated by the rapid and effective suppression of cell growth produced by exposure to the known FXR antagonist Z-Guggulsterone (Z-G) (see Figure 1).
  • Figure 3 shows that the three different THR agonists tested were all able to markedly increase cell growth rates over a 48 hour timescale.
  • Figure 4 shows that the six different PPAR agonists tested were also all able to markedly increase cell growth rates over a 48 hour timescale.
  • Figure 5 illustrates that the RXR/RAR agonists tested produced two distinct groups of influence. In the first group were those agonists found to induce proliferation such as 13-cis-retinoic acid, 9-cis-retinoic acid and 4-hydroxyretinoic acid. In the second group were those agonists found to suppress proliferation including all-trans-retinol, retinyl acetate and 13-cis-retinol.
  • NHR agonists which appear to reduce hES cell proliferation in an assay of the type described in this example may be useful in hES cell culture media, as well as those which are found to increase hES cell proliferation in such an assay, because of the complex nature of NHR signalling pathways, particularly when combinations of agonists are used.
  • the difference in the results in Figure 5 may be the result of the recruitment of different binding partners after RXR and/or RAR activation by the different RXR and RAR agonists tested.
  • the inventor's results suggest opposing ligand- specific signalling functions, but confirm that RXR and RAR agonists play a role in hES cell proliferation and self-renewal.
  • all-trans-retinol appears to reduce hES cell proliferation relative to the control in Figure 5, it has been shown to significantly improve hES cell culture when incorporated into a culture medium of the invention (see Examples 2 and 3).
  • the inventor further tested the effects of incorporating nuclear hormone receptor agonists into stem cell culture media.
  • the SA461 hES cell line was provided by Cellartis AB (G ⁇ teborg, Sweden) and initially expanded, as instructed by the provider, on mitotically inactivated mouse embryonic fibroblasts (MEFs).
  • the MEFs used in this case were isolated from the dl3 foetuses of pregnant ICR strain mice.
  • a conditioned medium was produced by conditioning VitrohES (Vitrolife AB) media containing 4ng/ml bFGF on mitotically inactivated MEFs seeded at 65,000 cells/cm 2 on a gelatinised culture surface at a ratio of 0.14ml/cm 2 for 24 hours before filter sterilising and storage at -80 0 C.
  • a fresh medium was also produced, consisting of DMEM/F12 (Invitrogen) containing SynthecholTM supplement (Invitrogen), transferrin, insulin and selenite, progesterone and putrescine (Invitrogen), L-glutamine lOO ⁇ M (Invitrogen) and DL-alpha tocopherol 30OnM (Sigma) to replace routine culture components which may be degraded or exhausted in the conditioned media by fibroblast exposure.
  • SynthecholTM supplement Invitrogen
  • transferrin transferrin
  • insulin and selenite insulin and selenite
  • progesterone and putrescine Invitrogen
  • L-glutamine lOO ⁇ M Invitrogen
  • DL-alpha tocopherol 30OnM Sigma
  • a combination of an RXR/RAR agonist (all-trans-retinol) and a THR agonist (3,5- diiodo-L-thyronine) produced expansive areas of morphologically acceptable hES-like cells with both peripheral and central regions of differentiation (Figure 25).
  • a combination of an FXR agonist (cholic acid), a THR agonist (3,5-diiodo-L-thyronine) and a RXR/RAR agonist (all-trans-retinol) allowed the growth of cell colonies exhibiting typical hES-like morphology without visible indication of differentiated cell types.
  • This particular cell culture medium was continued in culture and the cells characterised at passage 6 (see Example 3).
  • Example 3 Human ES cells cultured with a combination of NHR agonists retain an undifferentiated morphology and phenotype
  • a conditioned medium was produced as in Example 2.
  • a fresh medium was also produced, consisting of DMEM/F12 (Invitrogen) containing SynthecholTM supplement (Invitrogen), transferrin, insulin, selenite, progesterone and putrescine (Invitrogen), L- glutamine lOO ⁇ M (Invitrogen), DL-alpha tocopherol 30OnM (Sigma), the THR agonist 3,5-diiodo-L-thyronine (5OnM) (Biomol), the RXR/RAR agonist all-trans-retinol (3OnM) (Biomol), and the FXR agonist cholic acid (l ⁇ M) (Biomol).
  • DAPI Final con.: 0.5ug/ml; Oct-4: (1 :500), 2ary: Goat-a-mouse-IgG- FITC (1:150); SSEA-I : (1 :200), 2ary: Goat-a-Mouse-IgM-FITC (1 :150); SSEA-3: (1:200), 2ary: Goat-a-Rat-IgM-Cy3 (1 :150); SSEA-4: (1:200), 2ary: Goat-a-Mouse-IgG- FITC (1:150); TRA-1-60: (1 :200), 2ary: Goat-a-Mouse-IgM-FITC (1:150); TRA-1-81 : (1:200), 2ary: Goat-a-Mouse-IgM-FITC (1 :150)).
  • Karyotpye anatysis was also performed. Briefly, cells were incubated in culture with O.l ⁇ g/ml of colcemid, trypsinised, resuspended in 0.075M KCl then fixed in 3:1 methanol/acetic acid. After staining karotypes were examined and band analysis performed at Cellartis AB (G ⁇ teborg, Sweden). The cells, which were established from a male embryo, possessed a normal 46XY karyotype ( Figure 9).
  • the inventor's experiments show that an advantage of the culture media of the invention is that they can be used to culture pluripotent stem cells without feeder cell contact, i.e. they can be used to culture pluripotent stem cells in the absence of a layer of feeder cells.
  • the inventor's experiments show that another advantage of the culture media of the invention is that they can be used to rapidly expand a population of pluripotent stem cells, i.e. they allow large numbers of cells to be produced in a relatively short time.
  • the inventor's experiments show that a further advantage of the culture media of the invention is that they can be used to expand several different types of pluripotent stem cell lines, i. e. different types of pluripotent stem cell can be cultured using a single culture medium.
  • the inventor has already successfully tested the culture media and methods of the invention with the SA461 hES cell line (as described above), and preliminary results suggest that the same culture media and methods can be used with other hES cell lines.
  • the inventor's experiments also show that the culture media of the invention can be used without a step of adapting cells to the culture medium, as is commonly required when transferring pluripotent stem cells into a new culture medium.
  • the inventor's experimental data therefore suggest that the culture media of the invention benefit from significant advantages over known culture media in terms of the scalability, reproducibility and robustness of pluripotent stem cell culture.
  • Example 4 Human ES cells cultured with a combination of NHR agonists retain an undifferentiated morphology and phenotype - further experiments
  • this culture medium composition can assist in the maintenance of the typical morphology of an undifferentiated embryonic stem cell over multiple passages in a feeder-free culture system.
  • This culture medium composition was found to be particularly advantageous in improving pluripotent stem cell culture, in that it allows (to some extent) enzymatic passaging of cells in feeder-free culture.
  • Example 5 Human ES cells cultured with a combination of NHR agonists retain an undifferentiated morphology and phenotype — further experiments
  • a conditioned medium was produced as in Example 2.
  • a fresh medium was also produced using DMEM/F12 (Invitrogen) and transferrin, insulin, selenite, progesterone and putrescine (as N2 Supplement; Invitrogen), L-glutamine (Invitrogen) and B27 Supplement (Invitrogen).
  • the SA461 and SAl 21 hES cell lines (Cellartis AB, G ⁇ teborg, Sweden) were cultured continuously using enzymatic passage with trypsin for between 3 and 23 passages with a passage interval of 4-7 days to fresh fibronectin coated culture vessels. Immunostaining, karyotype analysis and QRTPCR were performed as described in Example 3.
  • In vitro differentiation was performed by transferring cells back to feeder based culture for one passage then manually cutting segments for embryoid body formation in suspension based culture in DMEM containing 10% FBS (both Invitrogen).
  • the culture medium composition described in this example has been found to be particularly advantageous in improving pluripotent stem cell culture.
  • the use of this culture medium composition provides an especially robust culture system. It has been found to support proliferation and enzymatic passaging of multiple hES cell lines in prolonged feeder-free culture (at least the SA461, SA121 and SAl 81 hES cell lines).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention porte sur de nouveaux milieux de culture et sur des procédés pour des cellules souches pluripotentes, en particulier des cellules souches embryonnaires humaines (hES), qui fournissent des avantages significatifs sur les milieux de culture connus. L'invention porte également sur les procédés correspondants. Les milieux de culture de l'invention comprennent, entre autres ingrédients, un agoniste de récepteur d'hormone nucléaire, en particulier un agoniste du récepteur farnésoïde X (FXR), un récepteur rétinoïde X (RXR) ou un agoniste du récepteur d'acide rétinoïque (RAR), un agoniste du récepteur activé par un proliférateur du peroxisome (PPAR) et/ou un agoniste du récepteur de l'hormone thyroïde (THR). L'invention porte également sur des suppléments de milieux de culture apparentés, sur des compositions et sur des utilisations.
PCT/GB2009/001404 2008-06-05 2009-06-05 Milieux de culture de cellules souches et procédés correspondants WO2009147400A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0810304.6 2008-06-05
GB0810304A GB0810304D0 (en) 2008-06-05 2008-06-05 Stem cell culture media and methods
GB0821363.9 2008-11-21
GB0821363A GB0821363D0 (en) 2008-11-21 2008-11-21 Stem cell culture media and methods

Publications (1)

Publication Number Publication Date
WO2009147400A1 true WO2009147400A1 (fr) 2009-12-10

Family

ID=40872420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001404 WO2009147400A1 (fr) 2008-06-05 2009-06-05 Milieux de culture de cellules souches et procédés correspondants

Country Status (2)

Country Link
GB (1) GB2460552B (fr)
WO (1) WO2009147400A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
WO2013184809A1 (fr) * 2012-06-05 2013-12-12 The Regents Of The University Of California Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes
WO2016072435A1 (fr) * 2014-11-06 2016-05-12 日本メナード化粧品株式会社 Agent destiné à maintenir des cellules souches à l'état indifférencié et agent destiné à favoriser leur croissance
US9376669B2 (en) 2012-11-01 2016-06-28 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9422577B2 (en) 2011-12-05 2016-08-23 Factor Bioscience Inc. Methods and products for transfecting cells
CN106906179A (zh) * 2017-04-28 2017-06-30 四川农业大学 一种高生长性多功能干细胞培养基
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
US10100279B2 (en) 2013-03-14 2018-10-16 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
US10137206B2 (en) 2016-08-17 2018-11-27 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019506431A (ja) * 2016-02-23 2019-03-07 ユニバーシティ−インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 幹細胞の効能改善のための組成物及び方法
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US12344572B2 (en) 2019-07-03 2025-07-01 Factor Bioscience Inc. Cationic lipids and transfection methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102375A1 (en) * 2002-05-15 2004-05-27 Massachusetts Institute Of Technology Methods to overcome inhibition of growth cone translocation
WO2004099395A2 (fr) * 2003-05-08 2004-11-18 Cellartis Ab Procede de generation de cellules souches neurales
WO2005103232A2 (fr) * 2004-04-23 2005-11-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Isolation et culture d'une population de grande purete de cellules photoreceptrices coniques par dissociation tissulaire et adherence specifique des pna, et applications biologiques associees

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4666567B2 (ja) * 2001-12-07 2011-04-06 ジェロン・コーポレーション ヒト胚幹細胞由来の膵島細胞
US8492145B2 (en) * 2002-06-24 2013-07-23 Mitsubishi Tanabe Pharma Corporation Process for producing nerve cells
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
KR20130100221A (ko) * 2005-06-22 2013-09-09 제론 코포레이션 인간 배아 줄기 세포의 현탁 배양
JP5680850B2 (ja) * 2006-03-30 2015-03-04 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｕｒｔ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｅｄｉｎｂｕｒｇｈ キナーゼインヒビターを含む培養培地およびその使用
GB0623635D0 (en) * 2006-11-27 2007-01-03 Stem Cell Sciences Uk Ltd Pluripotent cell growth media

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102375A1 (en) * 2002-05-15 2004-05-27 Massachusetts Institute Of Technology Methods to overcome inhibition of growth cone translocation
WO2004099395A2 (fr) * 2003-05-08 2004-11-18 Cellartis Ab Procede de generation de cellules souches neurales
WO2005103232A2 (fr) * 2004-04-23 2005-11-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Isolation et culture d'une population de grande purete de cellules photoreceptrices coniques par dissociation tissulaire et adherence specifique des pna, et applications biologiques associees

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEXANIAN A R ET AL: "Quiescent neural cells regain multipotent stem cell characteristics influenced by adult neural stem cells in co-culture", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 191, no. 1, 1 January 2005 (2005-01-01), pages 193 - 197, XP004676600, ISSN: 0014-4886 *
CHIN ET AL: "Identification of proteins from feeder conditioned medium that support human embryonic stem cells", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 130, no. 3, 19 June 2007 (2007-06-19), pages 320 - 328, XP022119696, ISSN: 0168-1656 *
GARCIA-GONZALO FRANCESC R ET AL: "Albumin-Associated Lipids Regulate Human Embryonic Stem Cell Self-Renewal", PLOS ONE, vol. 3, no. 1, January 2008 (2008-01-01), pages Article No.: e1384, XP002548861, ISSN: 1932-6203 *
GUNILLA CAISANDER ET AL: "Chromosomal integrity maintained in five human embryonic stem cell lines after prolonged in vitro culture", CHROMOSOME RESEARCH, KLUWER ACADEMIC PUBLISHERS, DO, vol. 14, no. 2, 1 March 2006 (2006-03-01), pages 131 - 137, XP019234937, ISSN: 1573-6849 *
LIU Y ET AL: "A novel chemical-defined medium with bFGF and N2B27 supplements supports undifferentiated growth in human embryonic stem cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 346, no. 1, 21 July 2006 (2006-07-21), pages 131 - 139, XP024925297, ISSN: 0006-291X, [retrieved on 20060721] *
MANNELLO F ET AL: "Concise review: No breakthroughs for human mesenchymal and embryonic stem cell culture: Conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not go", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 25, no. 7, 1 January 2007 (2007-01-01), pages 1603 - 1609, XP002466979, ISSN: 1066-5099 *
PROWSE ANDREW B J ET AL: "A proteome analysis of conditioned media from human neonatal fibroblasts used in the maintenance of human embryonic stem cells", PROTEOMICS, vol. 5, no. 4, March 2005 (2005-03-01), pages 978 - 989, XP002538300, ISSN: 1615-9853 *
PROWSE ANDREW B J ET AL: "Identification of potential pluripotency determinants for human embryonic stem cells following proteomic analysis of human and mouse fibroblast conditioned media", JOURNAL OF PROTEOME RESEARCH, vol. 6, no. 9, September 2007 (2007-09-01), pages 3796 - 3807, XP002538301, ISSN: 1535-3893 *

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562218B2 (en) 2011-12-05 2017-02-07 Factor Bioscience Inc. Reprogramming cells to a less differentiated state
US9969983B2 (en) 2011-12-05 2018-05-15 Factor Bioscience Inc. Methods and products for transfection
US9127248B2 (en) 2011-12-05 2015-09-08 Factor Bioscience Inc. Products for transfection and reprogramming
US12227757B2 (en) 2011-12-05 2025-02-18 Factor Bioscience Inc. Methods and products for transfecting cells
US12227768B2 (en) 2011-12-05 2025-02-18 Factor Bioscience Inc. Methods and products for transfection
US11708586B2 (en) 2011-12-05 2023-07-25 Factor Bioscience Inc. Methods and products for transfecting cells
US9399761B2 (en) 2011-12-05 2016-07-26 Factor Bioscience Inc. Methods of reprogramming cells to a less differentiated state
US9422577B2 (en) 2011-12-05 2016-08-23 Factor Bioscience Inc. Methods and products for transfecting cells
US11692203B2 (en) 2011-12-05 2023-07-04 Factor Bioscience Inc. Methods and products for transfecting cells
US10131882B2 (en) 2011-12-05 2018-11-20 Factor Bioscience Inc. Methods and products for transfection
US11492600B2 (en) 2011-12-05 2022-11-08 Factor Bioscience Inc. Methods and products for transfection
US11466293B2 (en) 2011-12-05 2022-10-11 Factor Bioscience Inc. Methods and products for transfecting cells
US10443045B2 (en) 2011-12-05 2019-10-15 Factor Bioscience Inc. Methods and products for transfection
US9605277B2 (en) 2011-12-05 2017-03-28 Factor Bioscience, Inc. Methods and products for transfecting cells
US10301599B2 (en) 2011-12-05 2019-05-28 Factor Bioscience Inc. Methods and products for transfection
US10982229B2 (en) 2011-12-05 2021-04-20 Factor Bioscience Inc. Methods and products for transfecting cells
US10829738B2 (en) 2011-12-05 2020-11-10 Factor Bioscience Inc. Methods and products for transfecting cells
US9695401B2 (en) 2011-12-05 2017-07-04 Factor Bioscience Inc. Methods and products for transfection
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
US10662410B1 (en) 2011-12-05 2020-05-26 Factor Bioscience Inc. Methods and products for transfecting cells
US9879228B2 (en) 2011-12-05 2018-01-30 Factor Bioscience Inc. Methods and products for transfection
US9605278B2 (en) 2011-12-05 2017-03-28 Factor Bioscience Inc. Methods and products for transfecting cells
US10472611B2 (en) 2011-12-05 2019-11-12 Factor Bioscience Inc. Methods and products for transfecting cells
WO2013184809A1 (fr) * 2012-06-05 2013-12-12 The Regents Of The University Of California Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
US9758797B2 (en) 2012-11-01 2017-09-12 Factor Bioscience, Inc. Methods and products for expressing proteins in cells
US9376669B2 (en) 2012-11-01 2016-06-28 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US11332758B2 (en) 2012-11-01 2022-05-17 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US11339409B2 (en) 2012-11-01 2022-05-24 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9657282B2 (en) 2012-11-01 2017-05-23 Factor Bioscience, Inc. Methods and products for expressing proteins in cells
US11339410B2 (en) 2012-11-01 2022-05-24 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US12006508B2 (en) 2012-11-01 2024-06-11 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10415060B2 (en) 2012-11-01 2019-09-17 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US11332759B2 (en) 2012-11-01 2022-05-17 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10752918B2 (en) 2012-11-01 2020-08-25 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10752919B2 (en) 2012-11-01 2020-08-25 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9464285B2 (en) 2012-11-01 2016-10-11 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9487768B2 (en) 2012-11-01 2016-11-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10590437B2 (en) 2012-11-01 2020-03-17 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9447395B2 (en) 2012-11-01 2016-09-20 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10767195B2 (en) 2012-11-01 2020-09-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10724053B2 (en) 2012-11-01 2020-07-28 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10752917B2 (en) 2012-11-01 2020-08-25 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10760048B2 (en) 2013-03-14 2020-09-01 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
US11884932B2 (en) 2013-03-14 2024-01-30 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
US10100279B2 (en) 2013-03-14 2018-10-16 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
US10124042B2 (en) 2014-01-31 2018-11-13 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
US12201675B2 (en) 2014-01-31 2025-01-21 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
JP2016086757A (ja) * 2014-11-06 2016-05-23 日本メナード化粧品株式会社 幹細胞の未分化状態維持剤及び増殖促進剤
WO2016072435A1 (fr) * 2014-11-06 2016-05-12 日本メナード化粧品株式会社 Agent destiné à maintenir des cellules souches à l'état indifférencié et agent destiné à favoriser leur croissance
US10259772B2 (en) 2014-11-06 2019-04-16 Nippon Menard Cosmetic Co., Ltd. Agents for maintaining undifferentiated state and promoting proliferation of stem cells
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP7154586B2 (ja) 2016-02-23 2022-10-18 ユニバーシティ－インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティ 幹細胞の効能改善のための組成物及び方法
JP2019506431A (ja) * 2016-02-23 2019-03-07 ユニバーシティ−インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 幹細胞の効能改善のための組成物及び方法
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11904023B2 (en) 2016-08-17 2024-02-20 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10894092B2 (en) 2016-08-17 2021-01-19 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10888627B2 (en) 2016-08-17 2021-01-12 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10137206B2 (en) 2016-08-17 2018-11-27 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10350304B2 (en) 2016-08-17 2019-07-16 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10363321B2 (en) 2016-08-17 2019-07-30 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10369233B2 (en) 2016-08-17 2019-08-06 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN106906179A (zh) * 2017-04-28 2017-06-30 四川农业大学 一种高生长性多功能干细胞培养基
US12344572B2 (en) 2019-07-03 2025-07-01 Factor Bioscience Inc. Cationic lipids and transfection methods
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US11814333B2 (en) 2019-07-30 2023-11-14 Factor Bioscience Inc. Cationic lipids and transfection methods
US10556855B1 (en) 2019-07-30 2020-02-11 Factor Bioscience Inc. Cationic lipids and transfection methods
US10611722B1 (en) 2019-07-30 2020-04-07 Factor Bioscience Inc. Cationic lipids and transfection methods
US10752576B1 (en) 2019-07-30 2020-08-25 Factor Bioscience Inc. Cationic lipids and transfection methods
US11242311B2 (en) 2019-07-30 2022-02-08 Factor Bioscience Inc. Cationic lipids and transfection methods

Also Published As

Publication number Publication date
GB0909765D0 (en) 2009-07-22
GB2460552A (en) 2009-12-09
GB2460552B (en) 2011-09-07

Similar Documents

Publication Publication Date Title
WO2009147400A1 (fr) Milieux de culture de cellules souches et procédés correspondants
US20230151326A1 (en) Simplified Compositions and Methods for Generating Neural Stem Cells from Human Pluripotent Stem Cells
JP5420837B2 (ja) 胚幹細胞の培地及び培養
US8685730B2 (en) Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
DK2737056T3 (en) Metabolic maturation in stem cell-derived tissue cells
EP2507360A1 (fr) Formulations et procedes de culture de cellules souches
Xu et al. Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells
EP1799811B1 (fr) Culture de cellules souches embryonnaires de primates
AU2013230020B2 (en) Defined media for expansion and maintenance of pluripotent stem cells
US10894944B2 (en) Cell culture media
WO2008148938A1 (fr) Formulations et procédés pour cultiver des cellules souches embryonnaires
EP3344758B1 (fr) Procédé in vitro de différenciation d'une population de cellules souches pluripotentes humaines en une population de cellules cardiomyocytaires
WO2013054112A1 (fr) Milieux de culture pour cellules souches pluripotentes
JP6913694B2 (ja) 多能性幹細胞のための培養培地
JP2019022509A (ja) 幹細胞および幹細胞に由来する細胞を単離するための、接着シグネチャーベースの方法
WO2012170853A1 (fr) Procédés et dispositifs pour la différenciation de cellules souches pluripotentes en cellules de la lignée pancréatique
Lu et al. Protocol for germ lineage differentiation of primed human pluripotent stem cells using chemically defined, nutrient-balanced media
Rajala et al. Effects of the physiochemical culture environment on the stemness and pluripotency of human embryonic stem cells
Wdziekonski et al. Differentiation of mouse embryonic stem cells and of human adult stem cells into adipocytes
JP6314193B2 (ja) 霊長類胚性幹細胞の培養
Hatch et al. Oligodendrocyte Differentiation from Human Embryonic Stem Cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09757772

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 09757772

Country of ref document: EP

Kind code of ref document: A1